Lo muthi usetshenziswa ngabesifazane ukusiza ekudambiseni ubuhlungu obumaphakathi kuya kobunzima ngenxa yesimo esibizwa nge-endometriosis.
Iselapha: Endometriosis
Amagama Brand: Orilissa
Isigaba Sezidakamizwa: Abaphikisi be-LHRH (GnRH).
Ukutholakala: Incwadi kadokotela iyadingeka
Ukukhulelwa: Gwema ukusetshenziswa ngesikhathi sokukhulelwa
Ukuncelisa: Bonana nodokotela ngaphambi kokusebenzisa

I-Elagolix iyi-oral bioavailable, isizukulwane sesibili, i-non-peptide esekelwe, i-molecule encane kanye ne-gonadotropin-releasing hormone (GnRH; LHRH) ekhethiwe yomphikisi, enomsebenzi ovimbela ukukhiqizwa kwamahomoni. Lapho iphathwa ngomlomo, i-elagolix incintisana ne-GnRH ngokubopha ama-receptor futhi ivimbele ukusayinda kwesamukeli se-GnRH kundlala yepituitary yangaphambili. Lokhu kuvimbela ukukhiqizwa kwehomoni ye-luteinizing (LH) kanye ne-follicle stimulating hormone (FSH). Kwabesilisa, ukuvinjelwa kwe-LH secretion kuvimbela ukukhululwa kwe-testosterone. Kwabesifazane, ukuvinjelwa kwe-FSH ne-LH kuvimbela ukukhiqizwa kwe-estrogen ngama-ovari. Ukuvinjelwa kokusayina kwe-GnRH kungase kwelaphe noma kuvimbele izimpawu zezifunda zezifo ezincike kumahomoni ocansi.

I-Elagolix iyi-oral, nonsteroidal gonadotropin releasing hormone (GnRH) ephikisayo eyehlisa ukukhiqizwa kwe-estrogen futhi isetshenziselwa ukwelapha izinhlobo ezibuhlungu ze-endometriosis kwabesifazane. Ukwelashwa kwe-Elagolix kuhlotshaniswa nezinga eliphansi lokuphakama kwe-serum enzyme ngesikhathi sokwelashwa futhi kusazoxhunyaniswa nezimo zokulimala kwesibindi okubonakala ngokomtholampilo.

I-Elagolix isetshenziswe ezivivinyweni zokutadisha isayensi eyisisekelo kanye nokwelashwa kwe-Endometriosis, i-Folliculogenesis, i-Uterine Fibroids, ukopha okunamandla kwesibeletho, kanye nokopha kakhulu kokuya esikhathini. Kusukela ngomhla zingama-24 kuJulayi 2018, nokho, i-US Food and Drug Administration (FDA) igunyaze i-elagolix ka-AbbVie ngaphansi kwegama lomkhiqizo i-Orilissa njengomphikisi wokuqala futhi okuwukuphela kwawo okhishwa ngomlomo we-gonadotropin-release hormone (GnRH) esungulwe ngokukhethekile abesifazane abanobuhlungu obumaphakathi kuya kobunzima be-endometriosis. Kutholakale ukuthi i-endometriosis ingenye yezifo ezivame kakhulu ze-gynecologic e-United States. Ikakhulukazi, izilinganiso ziphakamisa ukuthi oyedwa kwabesifazane abayishumi abaseminyakeni yokuzala uthintwa i-endometriosis futhi uhlangabezana nezimpawu zobuhlungu obuqeda amandla. Ngaphezu kwalokho, abesifazane abathintekayo yilesi simo bangahlupheka iminyaka engaba yisithupha kuya kweyishumi futhi bavakashele odokotela abaningi ngaphambi kokuthola ukuxilongwa okufanele. Kamuva, njengoba u-Orilissa (elagolix) agunyazwa yi-FDA ngaphansi kokubuyekezwa okubalulekile, lokhu kugunyazwa okusha okusheshisiwe kunikeza ochwepheshe bezokunakekelwa kwempilo enye inketho ebalulekile yokwelapha izidingo ezingaba khona zabesifazane abathintwe yi-endometriosis, kuya ngohlobo lwabo oluthile kanye nobukhulu bobuhlungu be-endometriosis. .

Isakhiwo samakhemikhali